Teleflex Incorporated has announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for its OEM Transaction with Lotus US Bidco Inc. expired on March 13, 2026. This marks a significant step towards the completion of the transaction, which is anticipated to close in the third quarter of 2026, pending other regulatory approvals. The OEM Agreement, entered into on December 9, 2025, involves the sale of certain assets and is part of Teleflex's strategy to streamline its operations and focus on core business areas. Additionally, the company is also navigating the regulatory landscape for its Acute Care and Urology Transaction with Intersurgical Limited, which has received a Second Request from the U.S. Federal Trade Commission, extending the waiting period under the HSR Act. This transaction is expected to be completed in the second half of 2026, subject to compliance with the FTC's request and other conditions outlined in the agreement. Overall, while the expiration of the HSR waiting period is a positive development, the ongoing regulatory scrutiny for the Acute Care and Urology Transaction introduces some uncertainty. Investors should monitor these developments closely as they may impact Teleflex's operational execution and strategic outlook.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.